Investor Centre
Investments for
better health
We are Anatara
We’re progressing innovative, evidence-based health solution
Anatara Lifesciences is developing and commercialising innovative, evidence-based health products to address significant unmet need, with a particular focus on conditions that involve the complexity of the gastrointestinal tract.
Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
Irritable Bowel Syndrome trial has reached interim
We’re delighted to share that Stage 1 of the GaRP Irritable Bowel Syndrome (IBS) trial has reached its interim. These results were announced late September 2023, and we’re encouraged by the absence of significant safety concerns. Our commitment to improving lives through research is stronger than ever.
Our People
Our team is driven by a shared passion for improving lives and transforming the landscape of gastrointestinal healthcare. Together, we bring diverse expertise, unwavering dedication, and a commitment to innovation.
Our Passionate
Researchers
Our team of researchers and scientists are at the forefront of gastrointestinal health research. With diverse backgrounds in biology, chemistry, and pharmacology, they worked tirelessly to develop the next generation of treatments.
We’ve now moved onto clinical research teams who match our level of passion for this exciting treatment.
Investor Centre Overview
Our Investor Center section is designed to provide you with the resources and knowledge you need for a successful partnership with us.
